Trial Profile
A randomised, placebo-controlled, double-dummy, double-blinded, cross-over study of evaluating individual and combined glucose-lowering effects of empagliflozin and LY2409021 in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Adomeglivant (Primary) ; Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Oct 2018 New trial record
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes